Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility 

While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients. 

Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments

After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types

Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy 

Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers

In this era of precision medicine, affordable profiling is essential  

The value of genomic testing is being increasingly demonstrated and will evolve over time 

Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients 

Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings